Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes.
Julie M Fox, Vicky Roy, Bronwyn M Gunn, Ling Huang, Melissa A Edeling, Matthias Mack, Daved H Fremont, Benjamin J Doranz, Syd Johnson, Galit Alter, Michael S Diamond
Sci Immunol | American Association for the Advancement of Science (AAAS) | Published : 2019
Chikungunya virus (CHIKV) is an emerging mosquito-borne virus that has caused explosive outbreaks worldwide. Although neutralizing monoclonal antibodies (mAbs) against CHIKV inhibit infection in animals, the contribution of Fc effector functions to protection remains unknown. Here, we evaluated the activity of therapeutic mAbs that had or lacked the ability to engage complement and Fcγ receptors (FcγR). When administered as post-exposure therapy in mice, the Fc effector functions of mAbs promoted virus clearance from infected cells and reduced joint swelling-results that were corroborated in antibody-treated transgenic animals lacking activating FcγR. The control of CHIKV infection by antibo..View full abstract
Awarded by NIAID NIH HHS